GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tyra Biosciences Inc (NAS:TYRA) » Definitions » ROIC %

Tyra Biosciences (Tyra Biosciences) ROIC % : -620.08% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tyra Biosciences ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Tyra Biosciences's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2024 was -620.08%.

As of today (2024-06-12), Tyra Biosciences's WACC % is 10.40%. Tyra Biosciences's ROIC % is -678.19% (calculated using TTM income statement data). Tyra Biosciences earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Tyra Biosciences ROIC % Historical Data

The historical data trend for Tyra Biosciences's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tyra Biosciences ROIC % Chart

Tyra Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
-64.17 -324.11 -1,414.09 -961.84 -669.75

Tyra Biosciences Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -596.54 -578.28 -731.30 -723.56 -620.08

Competitive Comparison of Tyra Biosciences's ROIC %

For the Biotechnology subindustry, Tyra Biosciences's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tyra Biosciences's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tyra Biosciences's ROIC % distribution charts can be found below:

* The bar in red indicates where Tyra Biosciences's ROIC % falls into.



Tyra Biosciences ROIC % Calculation

Tyra Biosciences's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-79.945 * ( 1 - 0% )/( (9.407 + 14.466)/ 2 )
=-79.945/11.9365
=-669.75 %

where

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=225.857 - 15.053 - ( 203.469 - max(0, 15.333 - 211.671+203.469))
=14.466

Tyra Biosciences's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2024 is calculated as:

ROIC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-89.288 * ( 1 - 0% )/( (14.466 + 14.333)/ 2 )
=-89.288/14.3995
=-620.08 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=225.857 - 15.053 - ( 203.469 - max(0, 15.333 - 211.671+203.469))
=14.466

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tyra Biosciences  (NAS:TYRA) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Tyra Biosciences's WACC % is 10.40%. Tyra Biosciences's ROIC % is -678.19% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Tyra Biosciences ROIC % Related Terms

Thank you for viewing the detailed overview of Tyra Biosciences's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tyra Biosciences (Tyra Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
2656 State Street, Carlsbad, CA, USA, 92008
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. Its lead product candidate is TYRA-300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
Executives
Daniel Bensen officer: Chief Operating Officer C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Todd Harris director, officer: Chief Executive Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Mva Investors, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Aaron I. Davis 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Alan Fuhrman officer: Chief Financial Officer C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
Ali D. Fawaz officer: General Counsel and Secretary C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
John Stephen Healy officer: General Counsel and Secretary C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD CA 92008
Boxer Capital, Llc 10 percent owner 12860 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Robert J More director, 10 percent owner 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
Alta Partners Nextgen Fund Ii, L.p. 10 percent owner 4 EMBARCADERO CENTER, SUITE 2100, SAN FRANCISCO CA 94111
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert L. Hudkins officer: Chief Technology Officer C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Siddarth Subramony director C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008
Melissa Mccracken director C/O TYRA BIOSCIENCES, INC, 2656 STATE STREET, CARLSBAD CA 92008